Tech Company Financing Transactions
LIfT BioSciences Funding Round
On 7/30/2025, LIfT BioSciences announced $13.7 million in investment from Enterprise Ireland.
Transaction Overview
Company Name
Announced On
7/30/2025
Transaction Type
Debt
Amount
$13,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to allocate the amount to conduct an investigator initiated clinical trial designed to test the feasibility and safety of IMAN therapy administered to patients with metastatic cervical cancer or head and neck cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
London BioScience Innovation Centre, 2 Royal College Street
London, NW1 0NH
UK
London, NW1 0NH
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
LIfT Biosciences is now moving into clinic with its unique allogeneic first-in-class neutrophil-based cell therapies using our patented N-LIfT Platform. LIfT is the only biotech company in the world with a Neutrophil Based Cell Therapy Platform (N-LIfT). The N-LIfT platform is flexible & unique which enables us to produce different types of Immuno-Modulatory Alpha Neutrophils (IMANs) for a wide range of different purposes. Different IMANs can be developed to treat cancers, auto-immune diseases, neurological conditions and anti-microbial resistance.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Blyth
Browse more venture capital transactions:
Prev: 7/30/2025: AIR venture capital transaction
Next: 7/30/2025: North Pole Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs